Skip to main content

Advertisement

SpringerLink
Log in

Identification of cystatin SN as a novel biomarker for pancreatic cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Cystatin SN (cystatin 1, CST1) is a member of the cystatin superfamily that inhibits the proteolytic activity of cysteine proteases. CST1 is a tumor biomarker that provides useful information for the diagnosis of esophageal, gastric, and colorectal carcinomas. However, the significance of CST1 in pancreatic cancer is unknown. The aim of this study was to assess whether CST1 is a potential biomarker for early diagnosis of malignant pancreatic neoplasms. Microarray analysis of mRNA extracted from pancreatic cancer and pancreatic normal tissues was performed. Bioinformatics revealed that CST1 was one of the highest expressed genes on the array in pancreatic cancer, compared with normal tissue. In addition, the upregulation of CST1 in pancreatic cancer and several pancreatic cancer cell lines was confirmed using real-time PCR (RT-PCR), immunohistochemistry, and Western blotting. Next, CST1 knockdown using siRNA reduced the expression of the proliferation-related proteins p-AKT and PCNA significantly, as well as colony formation and xenograft development in vitro. Consistent with this, CST1 mRNA overexpression was correlated closely with malignancy-associated proteins such as PCNA, cyclin D1, cyclin A2, and cyclin E in pancreatic cancer cell lines. In conclusion, our data suggest that CST1 might contribute to the proliferation of pancreatic cancer cells and could be a potential biomarker for the early detection of pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049–57.

    Article  CAS  PubMed  Google Scholar 

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  3. Guo X, Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas. 2005;31:13–22.

    Article  CAS  PubMed  Google Scholar 

  4. Costello E, Greenhalf W, Neoptolemos JP. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435–44.

    Article  CAS  PubMed  Google Scholar 

  5. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15–22.

    Article  PubMed  Google Scholar 

  6. Lah TT, Babnik J, Schiffmann E, Turk V, Skaleric U. Cysteine proteinases and inhibitors in inflammation: their role in periodontal disease. J Periodontol. 1993;64:485–91.

    CAS  PubMed  Google Scholar 

  7. Travis J, Potempa J. Bacterial proteinases as targets for the development of second-generation antibiotics. Biochim Biophys Acta. 2000;1477:35–50.

    Article  CAS  PubMed  Google Scholar 

  8. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta. 2000;291:113–35.

    Article  CAS  PubMed  Google Scholar 

  9. Barrett AJ. The cystatins: a diverse superfamily of cysteine peptidase inhibitors. Biomed Biochim Acta. 1986;45:1363–74.

    CAS  PubMed  Google Scholar 

  10. Dickinson DP, Zhao Y, Thiesse M, Siciliano MJ. Direct mapping of seven genes encoding human type 2 cystatins to a single site located at 20p11.2. Genomics. 1994;24:172–5.

    Article  CAS  PubMed  Google Scholar 

  11. Turk B, Turk V, Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem. 1997;378:141–50.

    CAS  PubMed  Google Scholar 

  12. Dickinson DP, Thiesse M, Hicks MJ. Expression of type 2 cystatin genes CST1-CST5 in adult human tissues and the developing submandibular gland. DNA Cell Biol. 2002;21:47–65.

    Article  CAS  PubMed  Google Scholar 

  13. Choi EH, Kim JT, Kim JH, Kim SY, Song EY, Kim JW, et al. Upregulation of the cysteine protease inhibitor, cystatin SN, contributes to cell proliferation and cathepsin inhibition in gastric cancer. Clin Chim Acta. 2009;406:45–51.

    Article  CAS  PubMed  Google Scholar 

  14. Yoneda K, Lida H, Endo H, Hosono K, Akiyama K, Takahashi H, et al. Identification of cystatin SN as a novel tumor marker for colorectal cancer. Int J Oncol. 2009;35:33–40.

    CAS  PubMed  Google Scholar 

  15. Kim JT, Lee SJ, Kang MA, Park JE, Kim BY, Yoon DY, et al. Cystatin SN neutralizes the inhibitory effect of cystatin C on cathepsin B activity. Cell Death Dis. 2013;19(4):e974.

    Article  Google Scholar 

  16. Chen YF, Ma G, Cao X, Luo RZ, He LR, He JH, et al. Overexpression of Cystatin SN positively affects survival of patients with surgically resected esophageal squamous cell carcinoma. BMC Surg. 2013;13:15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Lindahl P, Abrahamson M, Bjork I. Interaction of recombinant human cystatin C with the cysteine proteinases papain and actinidin. Biochem J. 1992;281:49–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Isemura S, Saitoh E, Sanada K, Minakata K. Identification of full-sized forms of salivary (S-type) cystatins (cystatin SN, cystatin SA, cystatin S, and two phosphorylated forms of cystatin S) in human whole saliva and determination of phosphorylation sites of cystatin S. J Biochem. 1991;110:648–54.

    Article  CAS  PubMed  Google Scholar 

  19. Thiesse M, Millar SJ, Dickinson DP. The human type 2 cystatin gene family consists of eight to nine members, with at least seven genes clustered at a single locus on human chromosome 20. DNA Cell Biol. 1994;13:97–116.

    Article  CAS  PubMed  Google Scholar 

  20. Henskens YM, Veerman EC, Nieuw Amerongen AV. Cystatins in health and diseases. Biol Chem Hoppe Seyler. 1996;37:71–86.

    Google Scholar 

  21. Buttle DJ, Burnett D, Abrahamson M. Levels of neutrophil elastase and cathepsin B activities, and cystatins in human sputum: relationship to inflammation. Scand J Clin Lab Invest. 1990;50:509–16.

    Article  CAS  PubMed  Google Scholar 

  22. Dickinson DP, Thiesse M, Dempsey LD, Millar SJ. Genomic cloning, physical mapping, and expression of human type 2 cystatin genes. Crit Rev Oral Biol Med. 1993;4:573–80.

    Article  CAS  PubMed  Google Scholar 

  23. Burka T, van der Noen H, Patil S. Cysteine proteinase inhibitor in cultured human medullary thyroid carcinoma cells. Lab Invest. 1992;66:691–700.

    Google Scholar 

  24. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christenser IJ, Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res. 2000;6:505–11.

    CAS  PubMed  Google Scholar 

  25. Sotiropoulou G, Anisowicz A, Sager R. Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer. J Biol Chem. 1997;272:903–10.

    Article  CAS  PubMed  Google Scholar 

  26. Haider AS, Peters SB, Kaporis H, Cardinale I, Fei J, Ott J, et al. Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol. 2006;126:869–81.

    Article  CAS  PubMed  Google Scholar 

  27. Vigneswaran N, Wu J, Zacharias W. Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumor to metastasis. Oral Oncol. 2003;39:559–68.

    Article  CAS  PubMed  Google Scholar 

  28. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin Am. 2002;16:37–52.

    Article  Google Scholar 

  29. Kokhanenko NI, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, et al. Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer. Vopr Onkol. 2001;47:294–7.

    CAS  PubMed  Google Scholar 

  30. Haglund C, Lundin J, Kuusela P, Roberts PJ. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer. 1994;70:487–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ventrucci M, Ubalducci GM, Cipolla A, Panella MA, Ligabue A. Serum CA 242: the search for a valid marker of pancreatic cancer. Clin Chem Lab Med. 1998;36:179–84.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, 510630, China

    Jie Jiang, Hui-Ling Liu, Zhi-Hao Liu, Si-Wei Tan & Bin Wu

Authors
  1. Jie Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui-Ling Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhi-Hao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Si-Wei Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bin Wu.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, J., Liu, HL., Liu, ZH. et al. Identification of cystatin SN as a novel biomarker for pancreatic cancer. Tumor Biol. 36, 3903–3910 (2015). https://doi.org/10.1007/s13277-014-3033-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-3033-3

Keywords

Search

Navigation